ClinicalTrials.gg

Program

BI 3034701

A development code. Also written as “BI 3034701 (C-14)”, “BI3034701 formulation II” and “BI3034701 formulation C1”.

In Boehringer Ingelheim's pipeline, GLP-1/GIP/NPY2 receptor agonist. Its studies are mostly in Obesity, led by Boehringer Ingelheim.

Furthest: phase 2, since Apr 30, 20266 company-led studies, 4 open or runningNext primary completion: Dec 15, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim64 open or runningphase 2since Apr 30, 2026Apr 3, 2024Dec 15, 2026phase 1 · NCT07837648
  • Named in Boehringer Ingelheim’s own pipeline as BI 3034701, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2024First study: phase 1 study in HealthyFirst studyNCT06352437 · 125 enrolled · Germany
  2. Apr 30, 2026Phase 2 study in ObesityPhase 2 reachedNCT07662122 · 345 enrolled · United States, Australia, Canada and more
  3. Jul 3, 20262 phase 1 studiesNCT07693231, NCT07708493
  4. Aug 5, 2026Phase 1 study in OverweightNCT07754474 · 70 planned · Germany
  5. Sep 18, 2026Phase 1 study in HealthyNCT07837648 · 30 planned · United Kingdom

Ahead

  1. Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07837648
  2. Dec 22, 2026Primary completion: phase 1 study in ObesityNCT07693231
  3. Jun 21, 2027Primary completion: phase 1 study in OverweightNCT07754474
  4. Jun 26, 2027Primary completion: phase 2 study in ObesityNCT07662122

TargetBeta

“GLP-1/GIP/NPY2 receptor agonist”the company's pipeline, read by Claude · source

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07837648Healthy · United Kingdom1RecruitingDec 15, 202630
NCT07754474Overweight · Germany1RecruitingJun 21, 202770
NCT07708493Healthy · Hungary1CompletedOct 29, 20268
NCT07693231Obesity · Japan1Active, not recruitingDec 22, 202648
NCT07662122Obesity · United States, Australia, Canada and more2Active, not recruitingJun 26, 2027345
NCT06352437Healthy · Germany1CompletedOct 7, 2025125

How it is read

Names in the registry

  • “BI 3034701”, 4 entries
  • “BI 3034701 (C-14)”, 1 entry
  • “BI3034701 formulation II”, 1 entry
  • “BI3034701 formulation C1”, 1 entry

Codes read as this program: BI3034701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.